As for assessing effects of the proposed therapy in AACD, this can be and indeed was performed numerous times with successful outcomes (using drugs suppressing the accumulation of AβPP-derived iAβ) in currently available transgenic mouse models where, as argued above, the second AD stage does not occur. The gene discussed is APP; the disease is Alzheimer disease.